# PDS Biotechnology Corp: overview PDSB · Nasdaq · CIK 1472091 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pdsb.md) · [Financials](/companies/pdsb/financials.md) · [Filings](/companies/pdsb/filings.md) · [Insiders](/companies/pdsb/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.29)](/filings/0001140361-25-041976.md) | not reported | [(0.21)](/filings/0001140361-26-021286.md) | [(0.21)](/filings/0001140361-26-032824.md) | [(0.19)](/filings/0001140361-25-041976.md) | not reported | [(0.13)](/filings/0001140361-26-021286.md) | [(0.18)](/filings/0001140361-26-032824.md) | | Free cash flow | $k | [(8,000) d](/filings/0001140361-25-041976.md) | [(8,234) d](/filings/0001140361-26-012030.md) | not reported | not reported | [(5,916) d](/filings/0001140361-25-041976.md) | [(3,703) d](/filings/0001140361-26-012030.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.66)](/filings/0001140361-23-014279.md) | [(1.43)](/filings/0001140361-24-016265.md) | [(1.39)](/filings/0001140361-25-010717.md) | [(1.03)](/filings/0001140361-26-012030.md) | [(0.74)](/filings/0001140361-26-012030.md) | | Free cash flow | $m | not reported | not reported | [(33.6)](/filings/0001140361-25-010717.md) | [(35.1)](/filings/0001140361-26-012030.md) | [(27.8)](/filings/0001140361-26-012030.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pdsb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.5m | 1,699,315 | | Added +68,226 | | [Focus Partners Wealth](/funds/1542153.md) | 2026-06-30 | $565.8k | 642,177 | | New +642,177 | | [Quantinno Capital Management LP](/funds/1759654.md) | 2026-06-30 | $565.8k | 642,177 | | New +642,177 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $535.4k | 607,639 | | Added +53,591 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $517.4k | 587,139 | | Reduced −73,089 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $314.6k | 357,144 | | Added +49,833 | | [Militia Capital Management LLC](/funds/2130487.md) | 2026-06-30 | $292.3k | 331,800 | | New +331,800 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $285.3k | 323,801 | | New +323,801 | | [Caption Management, LLC](/funds/1706766.md) | 2026-06-30 | $281.2k | 319,100 | Call | Unchanged | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $276.6k | 313,922 | | Added +310,000 | ## Recent filings [All 790 filings](/companies/pdsb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-21 | 23:59 ET | [8-K](/filings/0001140361-26-040283.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-040283 | | 2026-10-20 | 12:00 ET | [8-K](/filings/0001140361-26-040181.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-040181 | | 2026-10-06 | 12:05 ET | [8-K](/filings/0001140361-26-038728.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-038728 | | 2026-09-22 | 12:05 ET | [8-K](/filings/0001140361-26-037298.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-037298 | | 2026-09-21 | 01:56 ET | [SCHEDULE 13D](/filings/0001193125-26-397073.md) | Ownership report, active investor | 0001193125-26-397073 | | 2026-09-21 | 20:05 ET | [8-K](/filings/0001140361-26-037234.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-037234 | | 2026-09-14 | 20:10 ET | [8-K](/filings/0001140361-26-036489.md) | 1.02 Termination of a material agreement; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-036489 | | 2026-09-08 | 12:35 ET | [8-K](/filings/0001140361-26-035853.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-035853 | | 2026-09-04 | 21:25 ET | [8-K](/filings/0001140361-26-035809.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001140361-26-035809 | | 2026-08-25 | 20:08 ET | [8-K](/filings/0001140361-26-034320.md) | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors | 0001140361-26-034320 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001140361-26-012030.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1472091 - Tickers: PDSB - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.